BPC-157 therapy markedly attenuates cyclophosphamide-induced hemorrhagic cystitis in rats via a NO-system-related mechanism

Hemorrhagic cystitis, a severe and painful inflammation of the bladder lining characterized by bleeding, is a common and dose-limiting side effect of the chemotherapy drug cyclophosphamide. This condition is thought to involve a disturbance in the nitric oxide (NO) system. Current management strategies are often supportive and may not fully resolve the underlying damage. This study investigates the therapeutic potential of the stable gastric pentadecapeptide BPC-157 due to its known cytoprotective and tissue-healing properties. The research aims to clarify the role of the NO-system in this pathology by co-administering BPC-157 with the NO precursor L-arginine and the NO synthase inhibitor L-NAME, exploring a potential new treatment avenue for this debilitating chemotherapy side effect.

The study induced hemorrhagic cystitis in rats by administering cyclophosphamide (100 mg/kg/day, intraperitoneally) for three days. Following cyclophosphamide administration, rats were treated with BPC-157 (10 μg/kg/day or 10 ng/kg/day), given either intraperitoneally or orally in drinking water. Other groups received the NOS substrate L-arginine (100 mg/kg/day, IP) or the NOS blocker L-NAME (5 mg/kg/day, IP), alone or in combination with BPC-157. The primary endpoints were the assessment of gross and microscopic bladder lesions (urothelial necrosis, edema, hemorrhage, ulceration), bladder wet weight, and functional changes measured by leak point pressure.

Cyclophosphamide consistently induced severe hemorrhagic cystitis, characterized by gross lesions, urothelial necrosis, inflammation, and a dramatic increase in bladder wet weight. Functionally, it increased leak point pressure. While L-arginine attenuated the lesions, L-NAME aggravated them. BPC-157, at both high (10 μg/kg) and low (10 ng/kg) doses and via both oral and intraperitoneal routes, provided comprehensive protection.

BPC-157 markedly attenuated all cyclophosphamide-induced lesions, grossly and microscopically, consistently reduced the increased bladder wet weight, and fully reversed the increased leak point pressure back to normal values. This powerful therapeutic effect of BPC-157 was maintained even when co-administered with the damaging agent L-NAME. Similarly, BPC-157's benefits were observed when given with L-arginine or a combination of L-NAME and L-arginine, indicating its robust action in modulating the dysregulated NO-system underlying the pathology.

Written by TitrateLab, separately from the study summarized above.